Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on April 8, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Preliminary Q1 2026 acquired IPR&D charge of approximately $102 million pre-tax.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary Q1 2026 acquired IPR&D charge of approximately $102 million pre-tax
- Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.81
- Payments primarily tied to collaboration and licensing agreements, including equity premiums and development milestones
- Results remain unaudited and subject to financial statement closing procedures
- Non-GAAP EPS impact signals Regeneron views the charge as outside core operating performance despite its inclusion in adjusted results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.